Achieve Life Sciences Files 8-K for Regulation FD Disclosure

TL;DR

ACHV filed an 8-K for a Reg FD disclosure on 6/27. No major news, just compliance.

AI Summary

Achieve Life Sciences, Inc. filed an 8-K on June 27, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself. The company was formerly known as OncoGenex Pharmaceuticals, Inc. and Sonus Pharmaceuticals Inc.

Why It Matters

This filing indicates a formal disclosure event by Achieve Life Sciences, Inc. to comply with regulatory requirements, suggesting potential information release to the public.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure (8-K for Regulation FD) and does not report any new material events, financial changes, or significant business developments.

Key Players & Entities

• ACHIEVE LIFE SCIENCES, INC. (company) — Registrant
• June 27, 2024 (date) — Date of earliest event reported
• ONCOGENEX PHARMACEUTICALS, INC. (company) — Former company name
• SONUS PHARMACEUTICALS INC (company) — Former company name
• Delaware (jurisdiction) — State of Incorporation
• 22722 29th Drive SE , Suite 100 Bothell , WA 98021 (address) — Principal Executive Offices
• ( 604 ) 210-2217 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ACHV The NASDAQ Stock Mar
• $20 m — for a tranched facility amount of up to $20 million, maturing June 1, 2028, with inte

Filing Documents

• achv-20240627.htm (8-K) — 44KB
• 0000950170-24-078445.txt ( ) — 195KB
• achv-20240627.xsd (EX-101.SCH) — 50KB
• achv-20240627_htm.xml (XML) — 6KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure In June 2024, Achieve Life Sciences, Inc. (the "Company") entered into a non-binding term sheet to refinance and extend the maturity date of its outstanding term loans with Silicon Valley Bank and its affiliates ("SVB"). The term sheet provides for a tranched facility amount of up to $20 million, maturing June 1, 2028, with interest-only payments through at least December 31, 2025. The parties anticipate closing on the refinanced loan on or before the current loan maturity date of August 1, 2024; however, the term sheet is non-binding, and there is no assurance that the Company will be able to enter into a definitive agreement with SVB on the terms provided in the term sheet, or any at all.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the timing of, terms of, and ability to complete, the refinancing and extension of the outstanding term loans, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission (the "SEC") on May 9, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ACHIEVE LIFE SCIENCES, INC. Date: June 27, 2024 /s/ John Bencich John Bencich Chief Executive Officer (Principal Executive and Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR